Table 1.

Recent randomized phase III trials of adjuvant chemotherapy in NSCLC

^aIncluded in LACE meta-analysis [16].

^bCisplatin and vindesine; cisplatin, mitomycin, and ifosfamide; cisplatin, mitomycin, and vinblastine; and cisplatin and vinorelbine.

^cUnplanned subset analysis for patients with tumors ≥4 cm showed a survival benefit with adjuvant chemotherapy (HR, 0.69; p = .043).

Abbreviations: ALPI, Adjuvant Lung Project Italy; ANITA, Adjuvant Navelbine International Trialist Association; BLT, Big Lung Trial; CALGB, Cancer and Leukemia Group B; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; IALT, International Adjuvant Lung Trial; LACE, Lung Adjuvant Cisplatin Evaluation; NSCLC, non-small cell lung cancer; PORT, postoperative radiotherapy.